about
Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal propertiesEffects of Melaleuca alternifolia (tea tree) essential oil and the major monoterpene component terpinen-4-ol on the development of single- and multistep antibiotic resistance and antimicrobial susceptibilityTherapeutic Potential of Tea Tree Oil for ScabiesTerpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytesIn vitro data support the investigation of vinegar as an antimicrobial agent for PD-associated Pseudomonas exit site infections.Analysis of early mesothelial cell responses to Staphylococcus epidermidis isolated from patients with peritoneal dialysis-associated peritonitis.Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil.Safety, efficacy and provenance of tea tree (Melaleuca alternifolia) oil.Scabies: an ancient global disease with a need for new therapies.Effects of a Statewide Protocol for the Management of Peritoneal Dialysis-Related Peritonitis on Microbial Profiles and Antimicrobial Susceptibilities: A Retrospective Five-Year Review.Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopyInduction of necrosis and cell cycle arrest in murine cancer cell lines by Melaleuca alternifolia (tea tree) oil and terpinen-4-ol.Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia.Role of the MexAB-OprM efflux pump of Pseudomonas aeruginosa in tolerance to tea tree (Melaleuca alternifolia) oil and its monoterpene components terpinen-4-ol, 1,8-cineole, and alpha-terpineol.Uncontrolled, open-label, pilot study of tea tree (Melaleuca alternifolia) oil solution in the decolonisation of methicillin-resistant Staphylococcus aureus positive wounds and its influence on wound healing.Use of deception to achieve double-blinding in a clinical trial of Melaleuca alternifolia (tea tree) oil for the treatment of recurrent herpes labialis.Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil.The water-soluble components of the essential oil of Melaleuca alternifolia (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro.Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae.Tolerance of Pseudomonas aeruginosa to Melaleuca alternifolia (tea tree) oil is associated with the outer membrane and energy-dependent cellular processes.Ciprofloxacin and Clostridium difficile-associated diarrhoea.Effect of habituation to tea tree (Melaleuca alternifolia) oil on the subsequent susceptibility of Staphylococcus spp. to antimicrobials, triclosan, tea tree oil, terpinen-4-ol and carvacrol.Survey of the antimicrobial activity of commercially available Australian tea tree (Melaleuca alternifolia) essential oil products in vitro.Frequencies of resistance to Melaleuca alternifolia (tea tree) oil and rifampicin in Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis.Human pleural fluid is a potent growth medium for Streptococcus pneumoniae.Candida albicans adhesion to human epithelial cells and polystyrene and formation of biofilm is reduced by sub-inhibitory Melaleuca alternifolia (tea tree) essential oil.Antimicrobial activity of essential oils and other plant extracts.Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus.Susceptibility of methicillin-resistant Staphylococcus aureus to the essential oil of Melaleuca alternifolia.Prevalence of delayed hypersensitivity to the European standard series in a self-selected population.Effectiveness of hand-cleansing formulations containing tea tree oil assessed ex vivo on human skin and in vivo with volunteers using European standard EN 1499.Lack of evidence that essential oils affect puberty.In-vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida spp.Treatment of scabies using a tea tree oil-based gel formulation in Australian Aboriginal children: protocol for a randomised controlled trial.Diagnosis of Helicobacter pylori Infection in a High-prevalence Pediatric Population: A Comparison of 2 Fecal Antigen Testing Methods and SerologyAir sampling to assess potential generation of aerosolized viable bacteria during flow cytometric analysis of unfixed bacterial suspensionsAntimicrobial and anti-inflammatory activity of fiveTaxandria fragransoilsin vitroSusceptibility of pseudomonads to Melaleuca alternifolia (tea tree) oil and componentsAssessment of the antibacterial activity of tea tree oil using the European EN 1276 and EN 12054 standard suspension testsMelaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis
P50
Q24537344-C64C37BE-D20F-4D1F-A77F-F27017B5EB3BQ24604284-49A6A7E3-58A9-443F-9953-8B8BB7C7445AQ26770884-723D9192-91A0-4C1C-8127-6A5A3461C044Q28141061-A8CEC3BB-6310-4B35-BA52-031E95E87724Q31153516-5F928BA5-262A-4E92-8A14-59DF379565A4Q33724949-A7A0D807-1E00-4991-BE31-734A41FC93DCQ33724949-CD8EDEE3-6507-4352-B30E-4759DA4B4CBEQ34229744-F6626DBB-2CC3-45AA-A5DC-5E902E066E19Q34366053-1F282503-65F4-40B5-99E6-D91DB451BD20Q35677899-7516C058-489A-4F13-9977-FEB233057DA8Q38543677-5E5D8371-DF67-4F2C-880D-EF6F332695EDQ39651887-78685E57-3262-4F50-8FD9-E025A696479BQ39812791-E391F15F-5048-4C45-9880-768D8EAB5A53Q40993662-32A170FF-E0DC-4640-9233-CF889A21C4BDQ42068795-2007CFDF-6E70-4F17-B9C9-F916F132454FQ42600656-EB3DDF80-07A4-4002-A798-23466554E000Q42622703-228BA9BB-3077-4DE9-BC25-9473AE1DB1D7Q43005892-EDEA1E28-441C-4175-A09D-26C10D35DB08Q43630184-3F464853-0370-49F7-90B5-DEBEE36FD342Q44894396-4BC3C562-7FBF-484C-A324-D690197E6097Q44978555-87745AB4-56EF-431E-90E2-4C5636C9CA18Q45018815-52414148-9596-4562-9254-D66110AD74F7Q45128693-0FFB427F-EC6A-4870-9960-44F1DB921F92Q45915038-91885C01-C3CF-4635-BCC3-559855569170Q46637441-64A1B45B-C36E-4809-8479-6A8A4524B5FAQ47107555-6F84B910-8EF4-468F-A683-570628098E9DQ47761804-EA1F1B2D-835F-421E-81A3-F231FB5C3334Q50125289-0EB2C579-18C8-4CE1-9CC1-E7BFF76C411CQ54030475-6DA0F988-AD48-4CC8-AA2C-4F9BA0107BB2Q54178650-4E9800BC-AC44-443D-AD55-5AA1EE49AB6AQ54374346-DF783447-4A45-4098-866E-8350E8739421Q54491851-0D5CE841-A39D-4DE4-8C0B-D0A6E768336EQ55057695-8DEAC050-72B7-47DF-AFCD-DD87C0B9F960Q55068168-419581E4-84BE-43E7-960A-A150C240FED1Q55396369-A156491E-FC52-4ABC-897B-48A963FBC984Q56112194-F2128C92-5E5C-4BC2-B62A-CA9665781C1FQ58027682-D1BCD898-C4D2-4AC6-B502-C5308CCF3905Q59652873-1D91F518-147B-4B56-AC9F-8526109B9C71Q59652876-3B669230-2CE1-42F5-8A03-D0718E8204B2Q59652877-1D6E7C14-6A0D-4956-9153-208C43CE6CA0
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Christine F Carson
@nl
Christine F Carson
@sl
Christine F. Carson
@en
Christine F. Carson
@es
type
label
Christine F Carson
@nl
Christine F Carson
@sl
Christine F. Carson
@en
Christine F. Carson
@es
prefLabel
Christine F Carson
@nl
Christine F Carson
@sl
Christine F. Carson
@en
Christine F. Carson
@es
P214
P244
P1053
F-1521-2013
P106
P1153
7103390157
P21
P213
0000 0000 6392 3508
P214
P244
n2003145202
P31
P3829
P496
0000-0003-3669-1651
P734
P735
P7859
lccn-n2003145202